메뉴 건너뛰기




Volumn 120, Issue , 2017, Pages 11-19

The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes

Author keywords

CNS clinical trials; CNS drug development

Indexed keywords

AMINO ACID RECEPTOR AFFECTING AGENT; BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR AFFECTING AGENT; TISSUE PLASMINOGEN ACTIVATOR;

EID: 85006022098     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2016.03.021     Document Type: Review
Times cited : (260)

References (125)
  • 1
    • 84867521031 scopus 로고    scopus 로고
    • Novel concepts in excitotoxic neurodegeneration after stroke
    • Aarts, M.M., Arundine, M., Tymianski, M., Novel concepts in excitotoxic neurodegeneration after stroke. Expert Rev. Mol. Med. 5 (2003), 1–22.
    • (2003) Expert Rev. Mol. Med. , vol.5 , pp. 1-22
    • Aarts, M.M.1    Arundine, M.2    Tymianski, M.3
  • 2
    • 83055178597 scopus 로고    scopus 로고
    • Novartis to shut brain research facility
    • Abbott, A., Novartis to shut brain research facility. Nature 480 (2011), 161–162.
    • (2011) Nature , vol.480 , pp. 161-162
    • Abbott, A.1
  • 3
    • 84865840573 scopus 로고    scopus 로고
    • Where will the (new) drugs for traumatic brain injury treatment be coming from?
    • Agoston, D.V., Risling, M., Where will the (new) drugs for traumatic brain injury treatment be coming from?. Front. Neurol., 3, 2012, 27.
    • (2012) Front. Neurol. , vol.3 , pp. 27
    • Agoston, D.V.1    Risling, M.2
  • 4
    • 55949117032 scopus 로고    scopus 로고
    • Frequent amyloid deposition without significant cognitive impairment among the elderly
    • Aizenstein, H.J., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65 (2008), 1509–1517.
    • (2008) Arch. Neurol. , vol.65 , pp. 1509-1517
    • Aizenstein, H.J.1
  • 5
    • 6944255523 scopus 로고    scopus 로고
    • Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
    • Begley, D.J., Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104 (2004), 29–45.
    • (2004) Pharmacol. Ther. , vol.104 , pp. 29-45
    • Begley, D.J.1
  • 6
    • 33947323759 scopus 로고    scopus 로고
    • Lost in translation: treatment trials in the SOD1 mouse and in human ALS
    • Benatar, M., Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 26 (2007), 1–13.
    • (2007) Neurobiol. Dis. , vol.26 , pp. 1-13
    • Benatar, M.1
  • 7
    • 84890136755 scopus 로고    scopus 로고
    • Successes and failures for drugs in late-stage development for Alzheimer's disease
    • Berk, C., Sabbagh, M.N., Successes and failures for drugs in late-stage development for Alzheimer's disease. Drugs Aging 30 (2013), 783–792.
    • (2013) Drugs Aging , vol.30 , pp. 783-792
    • Berk, C.1    Sabbagh, M.N.2
  • 8
    • 42749094007 scopus 로고    scopus 로고
    • Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke
    • Besancon, E., et al. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol. Sci. 29 (2008), 268–275.
    • (2008) Trends Pharmacol. Sci. , vol.29 , pp. 268-275
    • Besancon, E.1
  • 9
    • 0033696608 scopus 로고    scopus 로고
    • Of mice and men (and women and children): scientific and ethical implications of animal models
    • Bird, S.J., Parlee, M.B., Of mice and men (and women and children): scientific and ethical implications of animal models. Prog. Neuropsychopharmacol. Biol. Psychiatry 24 (2000), 1219–1227.
    • (2000) Prog. Neuropsychopharmacol. Biol. Psychiatry , vol.24 , pp. 1219-1227
    • Bird, S.J.1    Parlee, M.B.2
  • 10
    • 70349119559 scopus 로고    scopus 로고
    • Rivastigmine for Alzheimer's Disease. Cochrane Database of Systematic Reviews
    • Birks, J.S., Chong, L.Y., Grimley, E.J., Rivastigmine for Alzheimer's Disease. Cochrane Database of Systematic Reviews. 2015.
    • (2015)
    • Birks, J.S.1    Chong, L.Y.2    Grimley, E.J.3
  • 11
    • 32944480791 scopus 로고    scopus 로고
    • Substance P (NK1) receptor antagonists—analgesics or not?
    • P. Holzer Springer Berlin Heidelberg
    • Boyce, S., Hill, R.G., Substance P (NK1) receptor antagonists—analgesics or not?. Holzer, P., (eds.) Tachykinins. Handbook of Experimental Pharmacology, vol. 164, 2004, Springer Berlin Heidelberg, 441–457.
    • (2004) Tachykinins. Handbook of Experimental Pharmacology , vol.164 , pp. 441-457
    • Boyce, S.1    Hill, R.G.2
  • 12
    • 0038745763 scopus 로고    scopus 로고
    • Animal models of mental retardation: from gene to cognitive function
    • Branchi, I., et al. Animal models of mental retardation: from gene to cognitive function. Neurosci. Biobehav Rev. 27 (2003), 141–153.
    • (2003) Neurosci. Biobehav Rev. , vol.27 , pp. 141-153
    • Branchi, I.1
  • 13
    • 84905823855 scopus 로고    scopus 로고
    • Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies
    • Broadstock, M., Ballard, C., Corbett, A., Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Expert Opin. Pharmacother. 15 (2014), 1797–1810.
    • (2014) Expert Opin. Pharmacother. , vol.15 , pp. 1797-1810
    • Broadstock, M.1    Ballard, C.2    Corbett, A.3
  • 14
    • 0030154620 scopus 로고    scopus 로고
    • Chemical chaperones correct the mutant phenotype of the delta-F508 cystic fibrosis transmembrane conductance regulator protein
    • Brown, C.R., et al. Chemical chaperones correct the mutant phenotype of the delta-F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1 (1996), 117–125.
    • (1996) Cell Stress Chaperones , vol.1 , pp. 117-125
    • Brown, C.R.1
  • 15
    • 77954145556 scopus 로고    scopus 로고
    • Fragile X mental retardation protein controls gating of the sodium-activated potassium channel slack
    • Brown, M.R., et al. Fragile X mental retardation protein controls gating of the sodium-activated potassium channel slack. Nat. Neurosci. 13 (2010), 819–821.
    • (2010) Nat. Neurosci. , vol.13 , pp. 819-821
    • Brown, M.R.1
  • 16
    • 80052784370 scopus 로고    scopus 로고
    • Potassium channel modulation and auditory processing
    • Brown, M.R., Kaczmarek, L.K., Potassium channel modulation and auditory processing. Hear Res. 279 (2011), 32–42.
    • (2011) Hear Res. , vol.279 , pp. 32-42
    • Brown, M.R.1    Kaczmarek, L.K.2
  • 17
    • 84863580562 scopus 로고    scopus 로고
    • Current and emerging therapies in multiple sclerosis: a systematic review
    • Castro-Borrero, W., et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther. Adv. Neurol. Disord. 5 (2012), 205–220.
    • (2012) Ther. Adv. Neurol. Disord. , vol.5 , pp. 205-220
    • Castro-Borrero, W.1
  • 18
    • 26844501218 scopus 로고    scopus 로고
    • Animal models of head trauma
    • Cernak, I., Animal models of head trauma. NeuroRx 2 (2005), 410–422.
    • (2005) NeuroRx , vol.2 , pp. 410-422
    • Cernak, I.1
  • 19
    • 0029060107 scopus 로고
    • A change in gating mode leading to increased intrinsic Cl- channel activity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease
    • Champigny, G., et al. A change in gating mode leading to increased intrinsic Cl- channel activity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease. EMBO J. 14 (1995), 2417–2423.
    • (1995) EMBO J. , vol.14 , pp. 2417-2423
    • Champigny, G.1
  • 20
    • 0034776532 scopus 로고    scopus 로고
    • Patterns of cognitive decline in presymptomatic alzheimer disease: a prospective community study
    • Chen, P., et al. Patterns of cognitive decline in presymptomatic alzheimer disease: a prospective community study. Arch. Gen. Psychiatry 58 (2001), 853–858.
    • (2001) Arch. Gen. Psychiatry , vol.58 , pp. 853-858
    • Chen, P.1
  • 21
    • 0035049854 scopus 로고    scopus 로고
    • The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury
    • Cheney, J.A., et al. The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J. Cereb. Blood Flow Metab. 21 (2001), 396–403.
    • (2001) J. Cereb. Blood Flow Metab. , vol.21 , pp. 396-403
    • Cheney, J.A.1
  • 22
    • 19544376511 scopus 로고    scopus 로고
    • Neuroprotection for ischemic stroke: two decades of success and failure
    • Cheng, Y.D., Al-Khoury, L., Zivin, J.A., Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 1 (2004), 36–45.
    • (2004) NeuroRx , vol.1 , pp. 36-45
    • Cheng, Y.D.1    Al-Khoury, L.2    Zivin, J.A.3
  • 23
    • 45049084923 scopus 로고    scopus 로고
    • Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings
    • Conn, P.J., Roth, B.L., Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33 (2008), 2048–2060.
    • (2008) Neuropsychopharmacology , vol.33 , pp. 2048-2060
    • Conn, P.J.1    Roth, B.L.2
  • 24
    • 79955511396 scopus 로고    scopus 로고
    • Translating promising preclinical neuroprotective therapies to human stroke trials
    • Cook, D.J., Tymianski, M., Translating promising preclinical neuroprotective therapies to human stroke trials. Expert Rev. Cardiovasc. Ther. 9 (2011), 433–449.
    • (2011) Expert Rev. Cardiovasc. Ther. , vol.9 , pp. 433-449
    • Cook, D.J.1    Tymianski, M.2
  • 25
    • 0034838257 scopus 로고    scopus 로고
    • Ischemic stroke: effects of etiology and patient age on the time course of the core apparent diffusion coefficient
    • Copen, W.A., et al. Ischemic stroke: effects of etiology and patient age on the time course of the core apparent diffusion coefficient. Radiology 221 (2001), 27–34.
    • (2001) Radiology , vol.221 , pp. 27-34
    • Copen, W.A.1
  • 26
    • 84860621838 scopus 로고    scopus 로고
    • The evolution of the cerebral blood volume abnormality in patients with ischemic stroke: a CT perfusion study
    • d'Esterre, C.D., Aviv, R.I., Lee, T.Y., The evolution of the cerebral blood volume abnormality in patients with ischemic stroke: a CT perfusion study. Acta Radiol. 53 (2012), 461–467.
    • (2012) Acta Radiol. , vol.53 , pp. 461-467
    • d'Esterre, C.D.1    Aviv, R.I.2    Lee, T.Y.3
  • 27
    • 0028933344 scopus 로고
    • Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS)
    • Dal Canto, M.C., Gurney, M.E., Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 676 (1995), 25–40.
    • (1995) Brain Res. , vol.676 , pp. 25-40
    • Dal Canto, M.C.1    Gurney, M.E.2
  • 28
    • 68749100878 scopus 로고    scopus 로고
    • Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator
    • del Zoppo, G.J., et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. Stroke 40 (2009), 2945–2948.
    • (2009) Stroke , vol.40 , pp. 2945-2948
    • del Zoppo, G.J.1
  • 29
    • 0026512066 scopus 로고
    • Identification of normal and pathological aging in prospectively studied nondemented elderly humans
    • Dickson, D.W., et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 13 (1992), 179–189.
    • (1992) Neurobiol. Aging , vol.13 , pp. 179-189
    • Dickson, D.W.1
  • 30
    • 38149033055 scopus 로고    scopus 로고
    • The 2007 Feinberg lecture: a new road map for neuroprotection
    • Donnan, G.A., The 2007 Feinberg lecture: a new road map for neuroprotection. Stroke 39 (2008), 242–248.
    • (2008) Stroke , vol.39 , pp. 242-248
    • Donnan, G.A.1
  • 31
    • 84866669849 scopus 로고    scopus 로고
    • Reviewing the role of Donepezil in the treatment of Alzheimer's disease
    • Doody, R.S., Cummings, J.L., Farlow, M.R., Reviewing the role of Donepezil in the treatment of Alzheimer's disease. Curr. Alzheimer Res. 9 (2012), 773–781.
    • (2012) Curr. Alzheimer Res. , vol.9 , pp. 773-781
    • Doody, R.S.1    Cummings, J.L.2    Farlow, M.R.3
  • 32
    • 0028126679 scopus 로고
    • Cloning and expression of a human large-conductance calcium-activated potassium channel
    • Dworetzky, S.I., Trojnacki, J.T., Gribkoff, V.K., Cloning and expression of a human large-conductance calcium-activated potassium channel. Brain Res. Mol. Brain Res. 27 (1994), 189–193.
    • (1994) Brain Res. Mol. Brain Res. , vol.27 , pp. 189-193
    • Dworetzky, S.I.1    Trojnacki, J.T.2    Gribkoff, V.K.3
  • 33
    • 0031886652 scopus 로고    scopus 로고
    • Duration of neuroprotective treatment for ischemic stroke
    • Dyker, A.G., Lees, K.R., Duration of neuroprotective treatment for ischemic stroke. Stroke 29 (1998), 535–542.
    • (1998) Stroke , vol.29 , pp. 535-542
    • Dyker, A.G.1    Lees, K.R.2
  • 34
    • 84868243529 scopus 로고    scopus 로고
    • Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (Ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner
    • Eckford, P.D.W., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (Ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J. Biol. Chem. 287 (2012), 36639–36649.
    • (2012) J. Biol. Chem. , vol.287 , pp. 36639-36649
    • Eckford, P.D.W.1
  • 35
    • 84948757442 scopus 로고    scopus 로고
    • Drug combinations in the treatment of neuropathic pain
    • Eisenberg, E., Suzan, E., Drug combinations in the treatment of neuropathic pain. Curr. Pain Headache Rep. 18 (2014), 1–8.
    • (2014) Curr. Pain Headache Rep. , vol.18 , pp. 1-8
    • Eisenberg, E.1    Suzan, E.2
  • 36
    • 84863669083 scopus 로고    scopus 로고
    • Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
    • pii: e000917
    • Farrimond, L.E., Roberts, E., McShane, R., Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open, 2, 2012 pii: e000917.
    • (2012) BMJ Open , vol.2
    • Farrimond, L.E.1    Roberts, E.2    McShane, R.3
  • 37
    • 85020242278 scopus 로고    scopus 로고
    • The scientific agenda for AIDS
    • University of Texas at Dallas National Academy of Sciences
    • Fauci, A.S., The scientific agenda for AIDS. Issues in Science and Technology. VoSummer, 2003, 2003, University of Texas at Dallas, National Academy of Sciences.
    • (2003) Issues in Science and Technology. VoSummer, 2003
    • Fauci, A.S.1
  • 38
    • 0043013350 scopus 로고    scopus 로고
    • Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case fatality in the late 20th century
    • Feigin, V.L., Lawes, C.M., Bennett, D.A., Anderson, C.S., Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case fatality in the late 20th century. Lancet Neurol. 2 (2003), 43–53.
    • (2003) Lancet Neurol. , vol.2 , pp. 43-53
    • Feigin, V.L.1    Lawes, C.M.2    Bennett, D.A.3    Anderson, C.S.4
  • 39
    • 62949129784 scopus 로고    scopus 로고
    • Translational medicine for stroke drug discovery: the pharmaceutical industry perspective
    • Feuerstein, G.Z., Chavez, J., Translational medicine for stroke drug discovery: the pharmaceutical industry perspective. Stroke 40 (2009), S121–S125.
    • (2009) Stroke , vol.40 , pp. S121-S125
    • Feuerstein, G.Z.1    Chavez, J.2
  • 40
    • 0032748815 scopus 로고    scopus 로고
    • Neuroprotection of acute ischemic stroke: where are we?
    • Fisher, M., Neuroprotection of acute ischemic stroke: where are we?. Neurosci. 5 (1999), 392–401.
    • (1999) Neurosci. , vol.5 , pp. 392-401
    • Fisher, M.1
  • 41
    • 0037975646 scopus 로고    scopus 로고
    • Recommendations for advancing development of acute stroke therapies: stroke therapy academic industry roundtable 3
    • Fisher, M., Stroke Therapy Academic Industry, R, Recommendations for advancing development of acute stroke therapies: stroke therapy academic industry roundtable 3. Stroke 34 (2003), 1539–1546.
    • (2003) Stroke , vol.34 , pp. 1539-1546
    • Fisher, M.1    Stroke Therapy Academic Industry, R,2
  • 42
    • 66849097996 scopus 로고    scopus 로고
    • Update of the stroke therapy academic industry roundtable preclinical recommendations
    • Fisher, M., et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40 (2009), 2244–2250.
    • (2009) Stroke , vol.40 , pp. 2244-2250
    • Fisher, M.1
  • 43
    • 84867530358 scopus 로고    scopus 로고
    • Identifying and utilizing the ischemic penumbra
    • Fisher, M., Bastan, B., Identifying and utilizing the ischemic penumbra. Neurology 79 (2012), S79–S85.
    • (2012) Neurology , vol.79 , pp. S79-S85
    • Fisher, M.1    Bastan, B.2
  • 44
    • 0030451306 scopus 로고    scopus 로고
    • Presymptomatic hippocampal atrophy in Alzheimer's disease
    • Fox, N.C., et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. Brain 119 (1996), 2001–2007.
    • (1996) Brain , vol.119 , pp. 2001-2007
    • Fox, N.C.1
  • 45
    • 0028985574 scopus 로고
    • Alzheimer-type neuropathology in transgenic mice overexpressing V717F [beta]-amyloid precursor protein
    • Games, D., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F [beta]-amyloid precursor protein. Nature 373 (1995), 523–527.
    • (1995) Nature , vol.373 , pp. 523-527
    • Games, D.1
  • 46
    • 0021894801 scopus 로고
    • Animal behavioral models in the discovery of compounds to treat memory dysfunction
    • Gamzu, E., Animal behavioral models in the discovery of compounds to treat memory dysfunction. Ann. N. Y. Acad. Sci. 444 (1985), 370–393.
    • (1985) Ann. N. Y. Acad. Sci. , vol.444 , pp. 370-393
    • Gamzu, E.1
  • 47
    • 84873487586 scopus 로고    scopus 로고
    • Genentech's Alzheimer's antibody trial to study disease prevention
    • Garber, K., Genentech's Alzheimer's antibody trial to study disease prevention. Nat. Biotech. 30 (2012), 731–732.
    • (2012) Nat. Biotech. , vol.30 , pp. 731-732
    • Garber, K.1
  • 48
    • 0036330007 scopus 로고    scopus 로고
    • Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions
    • Gladstone, D.J., et al. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33 (2002), 2123–2136.
    • (2002) Stroke , vol.33 , pp. 2123-2136
    • Gladstone, D.J.1
  • 49
    • 3142655729 scopus 로고    scopus 로고
    • Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy
    • Gotz, J., et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry 9 (2004), 664–683.
    • (2004) Mol. Psychiatry , vol.9 , pp. 664-683
    • Gotz, J.1
  • 50
    • 84930677623 scopus 로고    scopus 로고
    • Does long term use of psychiatric drugs cause more harm than good?
    • Gøtzsche, P.C., Young, A.H., Crace, J., Does long term use of psychiatric drugs cause more harm than good?. BMJ, 350, 2015, h2435.
    • (2015) BMJ , vol.350 , pp. h2435
    • Gøtzsche, P.C.1    Young, A.H.2    Crace, J.3
  • 51
    • 84947917035 scopus 로고    scopus 로고
    • Memantine ER/Donepezil: a review in Alzheimer's disease
    • Springer International Publishing
    • Greig, S., Memantine ER/Donepezil: a review in Alzheimer's disease. CNS Drugs, 2015, Springer International Publishing, 1–8.
    • (2015) CNS Drugs , pp. 1-8
    • Greig, S.1
  • 52
    • 0028247368 scopus 로고
    • The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel
    • Gribkoff, V.K., et al. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J. Biol. Chem. 269 (1994), 10983–10986.
    • (1994) J. Biol. Chem. , vol.269 , pp. 10983-10986
    • Gribkoff, V.K.1
  • 53
    • 9344266364 scopus 로고    scopus 로고
    • Effects of channel modulators on cloned large-conductance calcium-activated potassium channels
    • Gribkoff, V.K., et al. Effects of channel modulators on cloned large-conductance calcium-activated potassium channels. Mol. Pharmacol. 50 (1996), 206–217.
    • (1996) Mol. Pharmacol. , vol.50 , pp. 206-217
    • Gribkoff, V.K.1
  • 54
    • 0035052573 scopus 로고    scopus 로고
    • Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels
    • Gribkoff, V.K., et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. 7 (2001), 471–477.
    • (2001) Nat. Med. , vol.7 , pp. 471-477
    • Gribkoff, V.K.1
  • 55
    • 43349097329 scopus 로고    scopus 로고
    • The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update
    • Gribkoff, V.K., The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update. Expert Opin. Ther. Targets 12 (2008), 565–581.
    • (2008) Expert Opin. Ther. Targets , vol.12 , pp. 565-581
    • Gribkoff, V.K.1
  • 56
    • 84919625840 scopus 로고    scopus 로고
    • Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview
    • Grupke, S., et al. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview. Clin. Neurol. Neurosurg. 129 (2015), 1–9.
    • (2015) Clin. Neurol. Neurosurg. , vol.129 , pp. 1-9
    • Grupke, S.1
  • 57
    • 84857769209 scopus 로고    scopus 로고
    • Multiple sclerosis - remyelination failure as a cause of disease progression
    • Hagemeier, K., Bruck, W., Kuhlmann, T., Multiple sclerosis - remyelination failure as a cause of disease progression. Histol. Histopathol. 27 (2012), 277–287.
    • (2012) Histol. Histopathol. , vol.27 , pp. 277-287
    • Hagemeier, K.1    Bruck, W.2    Kuhlmann, T.3
  • 58
    • 85020245050 scopus 로고
    • L.M. Hardy Institute of Medicine, The National Academies of Sciences, Engineering and Medicine
    • Hardy, L.M., Hardy, L.M., (eds.) Government and industry collaboration in AIDS drug development, 1994, Institute of Medicine, The National Academies of Sciences, Engineering and Medicine, 1–18.
    • (1994) Government and industry collaboration in AIDS drug development , pp. 1-18
    • Hardy, L.M.1
  • 59
    • 84868632227 scopus 로고    scopus 로고
    • Why is publication of negative clinical trial data important?
    • Hayes, A., Hunter, J., Why is publication of negative clinical trial data important?. Br. J. Pharmacol. 167 (2012), 1395–1397.
    • (2012) Br. J. Pharmacol. , vol.167 , pp. 1395-1397
    • Hayes, A.1    Hunter, J.2
  • 60
    • 34250731169 scopus 로고    scopus 로고
    • Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies
    • Hazell, A.S., Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem. Int. 50 (2007), 941–953.
    • (2007) Neurochem. Int. , vol.50 , pp. 941-953
    • Hazell, A.S.1
  • 61
    • 79961220833 scopus 로고    scopus 로고
    • Disease modification in Parkinson's disease
    • Henchcliffe, C., Severt, W.L., Disease modification in Parkinson's disease. Drugs Aging 28 (2011), 605–615.
    • (2011) Drugs Aging , vol.28 , pp. 605-615
    • Henchcliffe, C.1    Severt, W.L.2
  • 62
    • 33750579981 scopus 로고    scopus 로고
    • Multiple sclerosis: new insights and trends
    • Inglese, M., Multiple sclerosis: new insights and trends. Am. J. Neuroradiol. 27 (2006), 954–957.
    • (2006) Am. J. Neuroradiol. , vol.27 , pp. 954-957
    • Inglese, M.1
  • 63
    • 0032174282 scopus 로고    scopus 로고
    • Formation of intermediate-conductance calcium-activated potassium channels by interaction of slack and slo subunits
    • Joiner, W.J., et al. Formation of intermediate-conductance calcium-activated potassium channels by interaction of slack and slo subunits. Nat. Neurosci. 1 (1998), 462–469.
    • (1998) Nat. Neurosci. , vol.1 , pp. 462-469
    • Joiner, W.J.1
  • 64
    • 84977933014 scopus 로고    scopus 로고
    • Half of US clinical trials go unpublished
    • Dec 3, 2013
    • Jones, N., Half of US clinical trials go unpublished. Nat. News, 2013 Dec 3, 2013.
    • (2013) Nat. News
    • Jones, N.1
  • 65
    • 33748943301 scopus 로고    scopus 로고
    • Non-conducting functions of voltage-gated ion channels
    • Kaczmarek, L.K., Non-conducting functions of voltage-gated ion channels. Nat. Rev. Neurosci. 7 (2006), 761–771.
    • (2006) Nat. Rev. Neurosci. , vol.7 , pp. 761-771
    • Kaczmarek, L.K.1
  • 66
    • 84904400166 scopus 로고    scopus 로고
    • Slack, slick and sodium-activated potassium channels
    • pii: 354262
    • Kaczmarek, L.K., Slack, slick and sodium-activated potassium channels. ISRN Neurosci., 2013, 2013 pii: 354262.
    • (2013) ISRN Neurosci. , vol.2013
    • Kaczmarek, L.K.1
  • 67
    • 84940983037 scopus 로고    scopus 로고
    • Modeling psychiatric disorders for developing effective treatments
    • Kaiser, T., Feng, G., Modeling psychiatric disorders for developing effective treatments. Nat. Med. 21 (2015), 979–988.
    • (2015) Nat. Med. , vol.21 , pp. 979-988
    • Kaiser, T.1    Feng, G.2
  • 68
    • 84940598230 scopus 로고    scopus 로고
    • CNS drugs take longer to develop, have lower success rates, than other drugs
    • K.I. Kaitin Tufts University, Tufts Center for the Study of Drug Development
    • Kaitlin, K.I., CNS drugs take longer to develop, have lower success rates, than other drugs. Kaitin, K.I., (eds.) Tufts CSDD Impact Reports, vol. 16, 2014, Tufts University, Tufts Center for the Study of Drug Development, 1–4.
    • (2014) Tufts CSDD Impact Reports , vol.16 , pp. 1-4
    • Kaitlin, K.I.1
  • 69
    • 0023851810 scopus 로고
    • Autoimmunity in multiple sclerosis
    • 371–371
    • Keyser, J.D., Autoimmunity in multiple sclerosis. Neurology, 38, 1988 371–371.
    • (1988) Neurology , vol.38
    • Keyser, J.D.1
  • 70
    • 0034983276 scopus 로고    scopus 로고
    • Trends in acute ischemic stroke trials through the 20th century
    • Kidwell, C.S., et al. Trends in acute ischemic stroke trials through the 20th century. Stroke 32 (2001), 1349–1359.
    • (2001) Stroke , vol.32 , pp. 1349-1359
    • Kidwell, C.S.1
  • 71
    • 0033542395 scopus 로고    scopus 로고
    • Effects of tissue plasminogen activator for acute ischemic stroke at one year
    • Kwiatkowski, T.G., et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N. Engl. J. Med. 340 (1999), 1781–1787.
    • (1999) N. Engl. J. Med. , vol.340 , pp. 1781-1787
    • Kwiatkowski, T.G.1
  • 73
    • 0036105484 scopus 로고    scopus 로고
    • Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
    • Lock, C., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002), 500–508.
    • (2002) Nat. Med. , vol.8 , pp. 500-508
    • Lock, C.1
  • 74
    • 84929292051 scopus 로고    scopus 로고
    • Time course and predictors of neurological deterioration after intracerebral hemorrhage
    • Lord, A.S., et al. Time course and predictors of neurological deterioration after intracerebral hemorrhage. Stroke 46 (2015), 647–652.
    • (2015) Stroke , vol.46 , pp. 647-652
    • Lord, A.S.1
  • 75
    • 0242610016 scopus 로고    scopus 로고
    • Topography and temporal resolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke
    • Markus, R., et al. Topography and temporal resolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke. Stroke 34 (2003), 2646–2652.
    • (2003) Stroke , vol.34 , pp. 2646-2652
    • Markus, R.1
  • 76
    • 84892371678 scopus 로고    scopus 로고
    • Animal models of CNS disorders
    • McGonigle, P., Animal models of CNS disorders. Biochem. Pharmacol. 87 (2014), 140–149.
    • (2014) Biochem. Pharmacol. , vol.87 , pp. 140-149
    • McGonigle, P.1
  • 77
    • 85020317969 scopus 로고    scopus 로고
    • New drug combination could extend life of cystic fibrosis patients
    • May 2015
    • McIntosh, J., New drug combination could extend life of cystic fibrosis patients. Medical News Today, vol. 18, 2015 May 2015.
    • (2015) Medical News Today , vol.18
    • McIntosh, J.1
  • 78
    • 77955114844 scopus 로고    scopus 로고
    • Is pharma running out of brainy ideas?
    • Miller, G., Is pharma running out of brainy ideas?. Science 329 (2010), 502–504.
    • (2010) Science , vol.329 , pp. 502-504
    • Miller, G.1
  • 79
    • 84861941975 scopus 로고    scopus 로고
    • Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
    • Miller, R.G., Mitchell, J.D., Moore, D.H., Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev., 2012, 10.1002/14651858.CD001447.pub3.
    • (2012) Cochrane Database Syst. Rev.
    • Miller, R.G.1    Mitchell, J.D.2    Moore, D.H.3
  • 80
    • 84884550190 scopus 로고    scopus 로고
    • Current and future therapies for multiple sclerosis
    • Minagar, A., Current and future therapies for multiple sclerosis. Scientifica 2013 (2013), 1–11.
    • (2013) Scientifica , vol.2013 , pp. 1-11
    • Minagar, A.1
  • 81
    • 0141836222 scopus 로고    scopus 로고
    • Excitatory amino acid antagonists for acute stroke
    • Muir, K.W., Lees, K.R., Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst. Rev., 2003, 10.1002/14651858.CD001244.
    • (2003) Cochrane Database Syst. Rev.
    • Muir, K.W.1    Lees, K.R.2
  • 82
    • 77957273984 scopus 로고    scopus 로고
    • Animal models of neuropsychiatric disorders
    • Nestler, E.J., Hyman, S.E., Animal models of neuropsychiatric disorders. Nat. Neurosci. 13 (2010), 1161–1169.
    • (2010) Nat. Neurosci. , vol.13 , pp. 1161-1169
    • Nestler, E.J.1    Hyman, S.E.2
  • 83
    • 84888199614 scopus 로고    scopus 로고
    • Imaging of cerebral ischemia: from acute stroke to chronic disorders
    • Nour, M., Liebeskind, D.S., Imaging of cerebral ischemia: from acute stroke to chronic disorders. Neurol. Clin. 32 (2014), 1–24.
    • (2014) Neurol. Clin. , vol.32 , pp. 1-24
    • Nour, M.1    Liebeskind, D.S.2
  • 84
    • 0038039305 scopus 로고    scopus 로고
    • Animal models of depression: are there any?
    • O'Neil, M.F., Moore, N.A., Animal models of depression: are there any?. Hum. Psychopharmacol. 18 (2003), 239–254.
    • (2003) Hum. Psychopharmacol. , vol.18 , pp. 239-254
    • O'Neil, M.F.1    Moore, N.A.2
  • 85
    • 33750924816 scopus 로고    scopus 로고
    • The blood-brain barrier and epilepsy
    • Oby, E., Janigro, D., The blood-brain barrier and epilepsy. Epilepsia 47 (2006), 1761–1774.
    • (2006) Epilepsia , vol.47 , pp. 1761-1774
    • Oby, E.1    Janigro, D.2
  • 86
    • 84863536950 scopus 로고    scopus 로고
    • N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease
    • Olivares, D., et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr. Alzheimer's Res., 9, 2012, 13.
    • (2012) Curr. Alzheimer's Res. , vol.9 , pp. 13
    • Olivares, D.1
  • 87
    • 84907054900 scopus 로고    scopus 로고
    • Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    • Panza, F., et al. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. Expert Opin. Biol. Ther. 14 (2014), 1465–1476.
    • (2014) Expert Opin. Biol. Ther. , vol.14 , pp. 1465-1476
    • Panza, F.1
  • 88
    • 84890992887 scopus 로고    scopus 로고
    • The roles of K+ channels in cancer
    • Pardo, L.A., Stuhmer, W., The roles of K+ channels in cancer. Nat. Rev. Cancer 14 (2014), 39–48.
    • (2014) Nat. Rev. Cancer , vol.14 , pp. 39-48
    • Pardo, L.A.1    Stuhmer, W.2
  • 89
    • 84868573143 scopus 로고    scopus 로고
    • Drug transport across the blood-brain barrier
    • Pardridge, W.M., Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 32 (2012), 1959–1972.
    • (2012) J. Cereb. Blood Flow Metab. , vol.32 , pp. 1959-1972
    • Pardridge, W.M.1
  • 90
    • 42649137566 scopus 로고    scopus 로고
    • Traumatic brain injury: can the consequences be stopped?
    • Park, E., Bell, J.D., Baker, A.J., Traumatic brain injury: can the consequences be stopped?. Can. Med. Assoc. J. 178 (2008), 1163–1170.
    • (2008) Can. Med. Assoc. J. , vol.178 , pp. 1163-1170
    • Park, E.1    Bell, J.D.2    Baker, A.J.3
  • 91
    • 84923331513 scopus 로고    scopus 로고
    • Building a roadmap for developing combination therapies for Alzheimer's disease
    • Perry, D., et al. Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev. Neurother. 15 (2015), 327–333.
    • (2015) Expert Rev. Neurother. , vol.15 , pp. 327-333
    • Perry, D.1
  • 92
    • 0033662408 scopus 로고    scopus 로고
    • Transgenic animals as models for human disease
    • Petters, R.M., Sommer, J.R., Transgenic animals as models for human disease. Transgenic Res. 9 (2000), 347–351.
    • (2000) Transgenic Res. , vol.9 , pp. 347-351
    • Petters, R.M.1    Sommer, J.R.2
  • 93
    • 60549107281 scopus 로고    scopus 로고
    • Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials
    • Philip, M., et al. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 40 (2009), 577–581.
    • (2009) Stroke , vol.40 , pp. 577-581
    • Philip, M.1
  • 94
    • 84930179409 scopus 로고    scopus 로고
    • Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease
    • Plosker, G., Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease. Drugs 75 (2015), 887–897.
    • (2015) Drugs , vol.75 , pp. 887-897
    • Plosker, G.1
  • 95
    • 85020310194 scopus 로고    scopus 로고
    • Orkambi, a new cystic fibrosis drug, wins F.D.A. approval
    • Pollack, A., Orkambi, a new cystic fibrosis drug, wins F.D.A. approval. The New York Times. July 2, 2015, 2015.
    • (2015) The New York Times. July 2, 2015
    • Pollack, A.1
  • 96
    • 0027289075 scopus 로고
    • The evolution of acute stroke recorded by multimodal magnetic resonance imaging
    • Quast, M.J., et al. The evolution of acute stroke recorded by multimodal magnetic resonance imaging. Magn. Reson Imaging 11 (1993), 465–471.
    • (1993) Magn. Reson Imaging , vol.11 , pp. 465-471
    • Quast, M.J.1
  • 97
    • 33645675839 scopus 로고    scopus 로고
    • Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease
    • Radad, K., Gille, G., Rausch, W.-D., Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol. Rep. 57 (2005), 701–712.
    • (2005) Pharmacol. Rep. , vol.57 , pp. 701-712
    • Radad, K.1    Gille, G.2    Rausch, W.-D.3
  • 98
    • 0024424270 scopus 로고
    • Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA
    • Riordan, J.R., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (1989), 1066–1073.
    • (1989) Science , vol.245 , pp. 1066-1073
    • Riordan, J.R.1
  • 99
    • 0027481813 scopus 로고
    • The cystic-fibrosis transmembrane conductance regulator
    • Riordan, J.R., The cystic-fibrosis transmembrane conductance regulator. Ann. Rev. Physiol. 55 (1993), 609–630.
    • (1993) Ann. Rev. Physiol. , vol.55 , pp. 609-630
    • Riordan, J.R.1
  • 100
    • 84877578442 scopus 로고    scopus 로고
    • Changing patterns in the epidemiology of traumatic brain injury
    • Roozenbeek, B., Maas, A.I.R., Menon, D.K., Changing patterns in the epidemiology of traumatic brain injury. Nat. Rev. Neurol. 9 (2013), 231–236.
    • (2013) Nat. Rev. Neurol. , vol.9 , pp. 231-236
    • Roozenbeek, B.1    Maas, A.I.R.2    Menon, D.K.3
  • 101
    • 85020308815 scopus 로고    scopus 로고
    • Mouse Models of Alzheimer's Disease: What Are They Modeling? 2015 Neuroscience Meeting Abstracts Online
    • Rose, G.M., Hayashi, E., Patrylo, P.R., Mouse Models of Alzheimer's Disease: What Are They Modeling? 2015 Neuroscience Meeting Abstracts Online. 2015.
    • (2015)
    • Rose, G.M.1    Hayashi, E.2    Patrylo, P.R.3
  • 102
    • 84879000844 scopus 로고    scopus 로고
    • Cystic fibrosis transmembrane regulator correctors and potentiators
    • pii: a009761
    • Rowe, S.M., Verkman, A.S., Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb. Perspect. Med., 3, 2013 pii: a009761.
    • (2013) Cold Spring Harb. Perspect. Med. , vol.3
    • Rowe, S.M.1    Verkman, A.S.2
  • 103
    • 84892695519 scopus 로고    scopus 로고
    • Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
    • Salloway, S., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370 (2014), 322–333.
    • (2014) N. Engl. J. Med. , vol.370 , pp. 322-333
    • Salloway, S.1
  • 104
    • 84941117181 scopus 로고    scopus 로고
    • Recent advances in the pharmacological management of acute and chronic pain
    • Schug, S.A., Goddard, C., Recent advances in the pharmacological management of acute and chronic pain. Ann. Palliat. Med. 3 (2014), 263–275.
    • (2014) Ann. Palliat. Med. , vol.3 , pp. 263-275
    • Schug, S.A.1    Goddard, C.2
  • 105
    • 39349107014 scopus 로고    scopus 로고
    • Design, power, and interpretation of studies in the standard murine model of ALS
    • Scott, S., et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 9 (2008), 4–15.
    • (2008) Amyotroph. Lateral Scler. , vol.9 , pp. 4-15
    • Scott, S.1
  • 106
    • 26844449402 scopus 로고    scopus 로고
    • Transgenic models of Alzheimer's disease: learning from animals
    • Spires, T.L., Hyman, B.T., Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2 (2005), 423–437.
    • (2005) NeuroRx , vol.2 , pp. 423-437
    • Spires, T.L.1    Hyman, B.T.2
  • 107
    • 79953093064 scopus 로고    scopus 로고
    • Drugs and clinical trials in neurodegenerative diseases
    • Stanzione, P., Tropepi, D., Drugs and clinical trials in neurodegenerative diseases. Ann. Ist. Super. Sanita 47 (2011), 49–54.
    • (2011) Ann. Ist. Super. Sanita , vol.47 , pp. 49-54
    • Stanzione, P.1    Tropepi, D.2
  • 108
    • 84924939833 scopus 로고    scopus 로고
    • Chapter 28-Recent developments in clinical trials for the treatment of traumatic brain injury
    • G. Jordan M.S. Andres Elsevier
    • Stein, D.G., Geddes, R.I., Sribnick, E.A., Chapter 28-Recent developments in clinical trials for the treatment of traumatic brain injury. Jordan, G., Andres, M.S., (eds.) Handbook of Clinical Neurology, vol. 127, 2015, Elsevier, 433–451.
    • (2015) Handbook of Clinical Neurology , vol.127 , pp. 433-451
    • Stein, D.G.1    Geddes, R.I.2    Sribnick, E.A.3
  • 109
    • 77955393170 scopus 로고    scopus 로고
    • Fragile X mental retardation protein is required for rapid experience-dependent regulation of the potassium channel Kv3.1b
    • Strumbos, J.G., et al. Fragile X mental retardation protein is required for rapid experience-dependent regulation of the potassium channel Kv3.1b. J. Neurosci. 30 (2010), 10263–10271.
    • (2010) J. Neurosci. , vol.30 , pp. 10263-10271
    • Strumbos, J.G.1
  • 110
    • 84878190712 scopus 로고    scopus 로고
    • Future viable models of psychiatry drug discovery in pharma
    • Sukoff Rizzo, S.J., et al. Future viable models of psychiatry drug discovery in pharma. J. Biomol. Screen. 18 (2013), 509–521.
    • (2013) J. Biomol. Screen. , vol.18 , pp. 509-521
    • Sukoff Rizzo, S.J.1
  • 111
    • 33846459373 scopus 로고    scopus 로고
    • Animal models relevant to schizophrenia and autism: validity and limitations
    • Tordjman, S., et al. Animal models relevant to schizophrenia and autism: validity and limitations. Behav. Genet. 37 (2007), 61–78.
    • (2007) Behav. Genet. , vol.37 , pp. 61-78
    • Tordjman, S.1
  • 112
    • 67651095785 scopus 로고    scopus 로고
    • Dosing of anti-psychotics in schizophrenia across the life spectrum
    • Uchida, H., Mamo, D.C., Dosing of anti-psychotics in schizophrenia across the life spectrum. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (2009), 917–920.
    • (2009) Prog. Neuropsychopharmacol. Biol. Psychiatry , vol.33 , pp. 917-920
    • Uchida, H.1    Mamo, D.C.2
  • 113
    • 80051544073 scopus 로고    scopus 로고
    • Animal models in the drug discovery pipeline for Alzheimer's disease
    • Van Dam, D., De Deyn, P.P., Animal models in the drug discovery pipeline for Alzheimer's disease. Br. J. Pharmacol. 164 (2011), 1285–1300.
    • (2011) Br. J. Pharmacol. , vol.164 , pp. 1285-1300
    • Van Dam, D.1    De Deyn, P.P.2
  • 115
    • 84882308754 scopus 로고    scopus 로고
    • Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force
    • Vellas, B., et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 9 (2013), 438–444.
    • (2013) Alzheimers Dement. , vol.9 , pp. 438-444
    • Vellas, B.1
  • 116
    • 0030981003 scopus 로고    scopus 로고
    • Riluzole: a new agent for amyotrophic lateral sclerosis
    • Wagner, M.L., Landis, B.E., Riluzole: a new agent for amyotrophic lateral sclerosis. Ann. Pharmacother. 31 (1997), 738–744.
    • (1997) Ann. Pharmacother. , vol.31 , pp. 738-744
    • Wagner, M.L.1    Landis, B.E.2
  • 117
    • 0033809127 scopus 로고    scopus 로고
    • Screening of antipsychotic drugs in animal models
    • Weiner, I., et al. Screening of antipsychotic drugs in animal models. Drug Dev. Res. 50 (2000), 235–249.
    • (2000) Drug Dev. Res. , vol.50 , pp. 235-249
    • Weiner, I.1
  • 118
    • 34447527791 scopus 로고    scopus 로고
    • Pathophysiology of traumatic brain injury
    • Werner, C., Engelhard, K., Pathophysiology of traumatic brain injury. Br. J. Anaesth. 99 (2007), 4–9.
    • (2007) Br. J. Anaesth. , vol.99 , pp. 4-9
    • Werner, C.1    Engelhard, K.2
  • 119
    • 0021348560 scopus 로고
    • The validity of animal models of depression
    • Willner, P., The validity of animal models of depression. Psychopharmacol. Berl. 83 (1984), 1–16.
    • (1984) Psychopharmacol. Berl. , vol.83 , pp. 1-16
    • Willner, P.1
  • 120
    • 0023000704 scopus 로고
    • Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case
    • Willner, P., Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog. Neuropsychopharmacol. Biol. Psychiatry 10 (1986), 677–690.
    • (1986) Prog. Neuropsychopharmacol. Biol. Psychiatry , vol.10 , pp. 677-690
    • Willner, P.1
  • 122
    • 84896734453 scopus 로고    scopus 로고
    • We can treat Alzheimer's disease successfully in mice but not in men: failure in translation? A perspective
    • Windisch, M., We can treat Alzheimer's disease successfully in mice but not in men: failure in translation? A perspective. Neurodegener. Dis. 13 (2014), 147–150.
    • (2014) Neurodegener. Dis. , vol.13 , pp. 147-150
    • Windisch, M.1
  • 123
    • 33747836278 scopus 로고    scopus 로고
    • Pharmacological activation and inhibition of slack (slo2.2) channels
    • Yang, B., et al. Pharmacological activation and inhibition of slack (slo2.2) channels. Neuropharmacology 51 (2006), 896–906.
    • (2006) Neuropharmacology , vol.51 , pp. 896-906
    • Yang, B.1
  • 124
    • 35448967751 scopus 로고    scopus 로고
    • Neuroprotection and stroke: time for a compromise
    • Young, A.R., et al. Neuroprotection and stroke: time for a compromise. J. Neurochem. 103 (2007), 1302–1309.
    • (2007) J. Neurochem. , vol.103 , pp. 1302-1309
    • Young, A.R.1
  • 125
    • 84982206792 scopus 로고    scopus 로고
    • Kv3.3 potassium channels and spinocerebellar ataxia
    • Oct. 7
    • Zhang, Y., Kaczmarek, L.K., Kv3.3 potassium channels and spinocerebellar ataxia. J. Physiol., 2015, 10.1113/JP271343 Oct. 7.
    • (2015) J. Physiol.
    • Zhang, Y.1    Kaczmarek, L.K.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.